Patents Assigned to Merck
  • Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
    Patent number: 7872030
    Abstract: (R/S)-(?/+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof and/or (S)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof are used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: January 18, 2011
    Assignee: Merck Patent GmbH
    Inventors: Gerd Bartoszyk, Herman Russ, Christoph Seyfried, Frank Weber
  • 5-Oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-Dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of Diabetes Typ 1 and 2
    Publication number: 20110009455
    Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof. The present invention relates to novel compounds of general formula (I) for use as glucokinase activators in the treatment of diabetes and obesity.
    Type: Application
    Filed: February 5, 2009
    Publication date: January 13, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Christoph Saal, Lars Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Expression Vectors Comprising the MCMV IE2 Promoter
    Publication number: 20110008839
    Abstract: The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein the expression vector does not contain any complete gene of the mCMV.
    Type: Application
    Filed: August 31, 2010
    Publication date: January 13, 2011
    Applicant: MERCK SERONO SA
    Inventors: Philippe Chatellard, Markus Imhof
  • ORGANIC SEMICONDUCTOR FORMULATION
    Publication number: 20110006265
    Abstract: The invention relates to a process for preparing a formulation comprising an organic semiconductor (OSC) and one or more organic solvents, to novel formulations obtained by this process, to their use as coating or printing inks for the preparation of organic electronic (OE) devices, especially organic field effect transistors (OFET) and organic photovoltaic (OPV) cells, to a process for preparing OE devices using the novel formulations, and to OE devices prepared from such a process or from the novel formulations.
    Type: Application
    Filed: February 6, 2009
    Publication date: January 13, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Mark James, Philip Edward May
  • CARBOXAMIDE-HETEROARYL DERIVATIVES FOR THE TREATMENT OF DIABETES
    Publication number: 20110009437
    Abstract: Novel heterocyclic compounds of the formula I wherein D is wherein R1, R2, E?, E?, E??, Y?, Y?, G?, G?, G?? and G?? have the meaning of claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Application
    Filed: February 3, 2009
    Publication date: January 13, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Lars Thore Burgdorf, Stefan Bender, Christoph Saal, Christine Charon, Norbert Beier
  • PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES
    Publication number: 20110009417
    Abstract: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z, W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
    Type: Application
    Filed: February 27, 2009
    Publication date: January 13, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Gerard Botton, Eric Valeur, Micheline Kergoat, Christine Charon, Samer Elbawab
  • ALIGNMENT FILM FOR LIQUID CRYSTALS OBTAINABLE BY DIRECT PARTICLE BEAM DEPOSITION
    Publication number: 20110007255
    Abstract: The invention relates to a process of preparing an alignment film for the alignment of liquid crystals (LCs) or reactive mesogens (RMs), by a direct particle beam deposition process, to an alignment film obtainable by said process, to the use of said alignment film for the alignment of LCs or RMs, especially in the form of thin layers, to a multilayer comprising said alignment film and one or more LC and/or RM layers, and to the use of the alignment film and multilayer in optical, electronic and electrooptical applications.
    Type: Application
    Filed: February 3, 2009
    Publication date: January 13, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Oleg Yaroshchuk, Eugene Telesh
  • METHOD AND DEVICE FOR THE THERMAL CONTROL OF TEMPERATURE-DEPENDENT ENZYMATIC REACTIONS USING MAGNETIC PARTICLES OR MAGNETIC BEADS AND ALTERNATING MAGNETIC FIELDS
    Publication number: 20110008797
    Abstract: The invention relates to a method for the thermal control of at least one temperature-dependent enzymatic reaction in the presence of magnetic particles, particularly nanoparticles, or magnetic beads in vitro by means of the heating of the magnetic beads or magnetic particles to at least one certain target temperature by means of alternating magnetic fields. The enzymatic reaction which can be controlled with the method according to the invention is preferably a PCR reaction or another reaction for the elongation or amplification of nucleic acids, including DNA, RNA or hybrids or derivatives thereof, which takes place directly on the functionalized magnetic beads. Further aspects of the invention relate to a reactor for carrying out the method and the use of the method or the reactor in analytics and diagnostics.
    Type: Application
    Filed: March 19, 2009
    Publication date: January 13, 2011
    Applicants: Fraunhofer-Gesellschaft zur Foederung der angewandten Forschung e.V., Merck Patent GmbH
    Inventors: Christian Zilch, Wilhelm Gerdes, Johann Bauer, Karl Holschuh
  • N-hydroxyamide derivatives and use thereof
    Patent number: 7868009
    Abstract: The present invention is related to N-hydroxyamide derivatives of Formula (I): and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
    Type: Grant
    Filed: January 27, 2006
    Date of Patent: January 11, 2011
    Assignee: Merck Serono, S.A.
    Inventors: Dominique Swinnen, Jerome Gonzalez
  • Preparation containing oxidized flavonoid derivatives
    Patent number: 7867993
    Abstract: The invention relates to novel compositions, in particular cosmetic and/or pharmaceutical compositions or food supplements, comprising at least one oxidized flavonoid derivative of the formula I, to novel oxidized flavonoid derivatives, and to novel uses of the oxidized flavonoid derivatives.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: January 11, 2011
    Assignee: Merck Patent GmbH
    Inventors: Christophe Carola, Sylvia Huber, Herwig Buchholz
  • 2-(hetero)-aryl substituted tetrahydroquinoline derivatives
    Patent number: 7868172
    Abstract: Compounds of the formula I, in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: January 11, 2011
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Ulrich Emde, Dirk Finsinger, Johannes Gleitz, Helmut Reubold, Frank Zenke
  • 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases
    Publication number: 20110003862
    Abstract: Compounds of the formula (I), inhibit D-amino acid oxidase and hence find use in treating degenerative and psychiatric diseases.
    Type: Application
    Filed: February 15, 2007
    Publication date: January 6, 2011
    Applicants: MERCK SHARP & DOHME LIMITED, MERCK & CO., INC.
    Inventors: Philip E. Brandish, Nicholas Brandon, Alister Campbell, Timothy Sparey
  • Liquid-crystalline medium and liquid crystal display
    Publication number: 20110001089
    Abstract: The invention relates to a liquid-crystalline medium comprising one or more compounds of the formula I in which R0, X0 and L1-6 have the meanings indicated in Claim 1, and to the use thereof in electro-optical liquid-crystal displays.
    Type: Application
    Filed: February 18, 2009
    Publication date: January 6, 2011
    Applicant: Merck Patent Gesellschaft
    Inventors: Michael Wittek, Brigitte Schuler, Volker Reiffenrath, Mark Goebel, Markus Czanta
  • Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
    Patent number: 7863312
    Abstract: The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: January 4, 2011
    Assignee: Merck Serono SA
    Inventors: Gian Luca Araldi, Yihua Liao, Adulla P. Reddy, Zhong Zhao
  • G-CSF polypeptides and uses thereof
    Patent number: 7863018
    Abstract: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: January 4, 2011
    Assignee: Merck Serono SA
    Inventors: Catherine Gonthier, Philippe Millasseau
  • G-CSF polypeptides and uses thereof
    Patent number: 7863016
    Abstract: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: January 4, 2011
    Assignee: Merck Serono S.A.
    Inventors: Catherine Gonthier, Philippe Millasseau
  • Halogen-free ionic liquids
    Patent number: 7863458
    Abstract: An ionic liquid according to the invention is substantially halogen-free, has a low viscosity and is stable to hydrolytic degradation under test conditions. The ionic liquid is a compound of the formula (cation) (R?—O—SO3), (cation) (R?—SO3), or a mixture of the two compounds. It can be used in processes for the chemical conversion and separation of materials by employing the ionic liquid as a solvent, solvent additive, extraction agent or phase-transfer catalyst. It can also be used in a heat exchange device wherein the ionic liquid serves as a heat carrier or heat carrier additive.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: January 4, 2011
    Assignee: Merck Patent GmbH
    Inventors: Peter Wasserscheid, Andreas Bösmann, Roy Van Hal
  • Antifungal agents
    Patent number: 7863465
    Abstract: The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-?-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 4, 2011
    Assignees: Merck Sharp & Dohme Corp., Scynexis, Inc.
    Inventors: James M. Balkovec, Frances Aileen Bouffard, Bruno Tse, James Dropinski, Dongfang Meng, Mark L. Greenlee, Michael Peel, Weiming Fan, Ahmed Mamai, Hao Liu, Keqaing Li
  • UV filters
    Patent number: 7863478
    Abstract: The invention relates to compounds of the formula (I) or (II), to compositions which comprise such compounds, to corresponding processes for the preparation of the compounds or the compositions comprising same, and to the use thereof as light-protection filters.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: January 4, 2011
    Assignee: Merck Patent GmbH
    Inventors: Christophe Carola, Frank Pfluecker, Herwig Buchholz, Hansjürgen Driller, Hans Neunhoeffer, Evgeniy V. Blyumin
  • Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
    Patent number: 7863328
    Abstract: Compounds of the formula (1) in which R1, R2, X, Y and Z are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: January 4, 2011
    Assignee: Merck Patent GmbH
    Inventors: Michel Brunet, Nathalie Adje, Valérie Guyard-Dangremont, Francis Contard